Peer-reviewed veterinary case report
Ivermectin treatment lowers tear production and affects eye health
By Kocaman, Yakup & Yanmaz, Latif Emrah·Published in Veterinary ophthalmology·2026·Department of Surgery·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Systemic Ivermectin Administration Reduces Aqueous Tear Production and Affects Ocular Surface Health in Clinically Healthy Dogs.
- Species:
- dog
Plain-English summary
A study found that 128 mixed-breed dogs given ivermectin, a common medication, showed a significant decrease in tear production and more signs of dry eye compared to those not treated with the drug. The treated dogs had lower scores on tear tests and were more likely to show issues with their eye surface. This suggests that even at recommended doses, ivermectin can lead to dry eye problems in some dogs. If your dog is on ivermectin, it might be a good idea to have their tear production checked by your vet.
People also search for: dog dry eye symptoms · ivermectin side effects in dogs · how to treat dog tear production issues
Abstract
PURPOSE: This study aimed to evaluate the effects of ivermectin administration on aqueous tear production and ocular surface health in dogs and to investigate its potential association with quantitative keratoconjunctivitis sicca (KCS). METHODS: A total of 128 mixed-breed dogs were included: 64 ivermectin-treated and 64 untreated controls. Lacrimal secretion and ocular surface status were assessed using Schirmer tear test I (STT-I), fluorescein staining, and corneal opacity scoring. Data were analyzed with nonparametric tests, with p < 0.05 considered significant. RESULTS: At 36 h after treatment, STT-I values were significantly reduced from baseline in the ivermectin group (p < 0.001), whereas no significant change was observed in controls (p > 0.05). Reduction in aqueous tear production (ΔSTT-I) was greater in ivermectin-treated dogs (-4.38 ± 2.7 mm/min, p < 0.001) than in controls (-0.14 ± 0.9 mm/min; p < 0.001). Mean STT-I at 36 h was lower in the treated group (6.05 ± 3.5 mm/min) compared with controls (10.08 ± 3.2 mm/min; p < 0.001). Fluorescein uptake was observed more frequently in ivermectin-treated dogs (32.8%, p = 0.001) than in controls (7.8%, p = 0.001). KCS severity scores were significantly higher in the ivermectin group (p < 0.05), while the control median score was 1. CONCLUSIONS: Routine systemic ivermectin treatment was associated with reduced aqueous tear production. The mechanism was not evaluated but may involve altered neural control of lacrimal secretion. Even at recommended doses, ivermectin may predispose susceptible dogs to subclinical dry eye; therefore, quantitative tear testing is advisable in dogs receiving ivermectin prophylaxis.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41963771/